Benefit of Preemptive Pharmacogenetic Information on Clinical Outcome

被引：68

作者：

Roden, Dan M. ^{[1
,2
,3
]}

Van Driest, Sara L. ^{[1
,4
]}

Mosley, Jonathan D. ^{[1
,3
]}

Wells, Quinn S. ^{[1
]}

Robinson, Jamie R. ^{[3
,5
]}

Denny, Joshua C. ^{[1
,3
]}

Peterson, Josh F. ^{[1
,3
]}

机构：

[1] Vanderbilt Univ, Med Ctr, Dept Med, Nashville, TN 37235 USA

[2] Vanderbilt Univ, Med Ctr, Dept Pharmacol, Nashville, TN 37235 USA

[3] Vanderbilt Univ, Med Ctr, Dept Biomed Informat, Nashville, TN 37235 USA

[4] Vanderbilt Univ, Med Ctr, Dept Pediat, Nashville, TN 37232 USA

[5] Vanderbilt Univ, Dept Surg, Med Ctr, Nashville, TN 37240 USA

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2018年 / 103卷 / 05期

基金：

美国国家卫生研究院;

关键词：

COST-EFFECTIVENESS; PERSONALIZED MEDICINE; IMPLEMENTATION CONSORTIUM; CARDIOVASCULAR EVENTS; GENETIC-DETERMINANTS; ANTIPLATELET THERAPY; PRECISION MEDICINE; DECISION-SUPPORT; RANDOMIZED-TRIAL; INDUCED MYOPATHY;

D O I：

10.1002/cpt.1035

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The development of new knowledge around the genetic determinants of variable drug action has naturally raised the question of how this new knowledge can be used to improve the outcome of drug therapy. Two broad approaches have been taken: a point-of-care approach in which genotyping for specific variant(s) is undertaken at the time of drug prescription, and a preemptive approach in which multiple genetic variants are typed in an individual patient and the information archived for later use when a drug with a pharmacogenetic story is prescribed. This review addresses the current state of implementation, the rationale for these approaches, and barriers that must be overcome. Benefits to pharmacogenetic testing are only now being defined and will be discussed.

引用

页码：787 / 794

页数：8

共 88 条

[1] Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications [J].

Aithal, GP ;

Day, CP ;

Kesteven, PJL ;

Daly, AK .

LANCET, 1999, 353 (9154) :717-719

[2]

Bank P.C., 2017, CLIN PHARM THER

[3] Development and use of active clinical decision support for preemptive pharmacogenomics [J].

Bell, Gillian C. ;

Crews, Kristine R. ;

Wilkinson, Mark R. ;

Haidar, Cyrine E. ;

Hicks, J. Kevin ;

Baker, Donald K. ;

Kornegay, Nancy M. ;

Yang, Wenjian ;

Cross, Shane J. ;

Howard, Scott C. ;

Freimuth, Robert R. ;

Evans, William E. ;

Broeckel, Ulrich ;

Relling, Mary V. ;

Hoffman, James M. .

JOURNAL OF THE AMERICAN MEDICAL INFORMATICS ASSOCIATION, 2014, 21 (E1) :E93-E99

[4] Preemptive Genotyping for Personalized Medicine: Design of the Right Drug, Right Dose, Right Time-Using Genomic Data to Individualize Treatment Protocol [J].

Bielinski, Suzette J. ;

Olson, Janet E. ;

Pathak, Jyotishman ;

Weinshilboum, Richard M. ;

Wang, Liewei ;

Lyke, Kelly J. ;

Ryu, Euijung ;

Targonski, Paul V. ;

Van Norstrand, Michael D. ;

Hathcock, Matthew A. ;

Takahashi, Paul Y. ;

McCormick, Jennifer B. ;

Johnson, Kiley J. ;

Maschke, Karen J. ;

Vitek, Carolyn R. Rohrer ;

Ellingson, Marissa S. ;

Wieben, Eric D. ;

Farrugia, Gianrico ;

Morrisette, Jody A. ;

Kruckeberg, Keri J. ;

Bruflat, Jamie K. ;

Peterson, Lisa M. ;

Blommel, Joseph H. ;

Skierka, Jennifer M. ;

Ferber, Matthew J. ;

Black, John L. ;

Baudhuin, Linnea M. ;

Klee, Eric W. ;

Ross, Jason L. ;

Veldhuizen, Tamra L. ;

Schultz, Cloann G. ;

Caraballo, Pedro J. ;

Freimuth, Robert R. ;

Chute, Christopher G. ;

Kullo, Iftikhar J. .

MAYO CLINIC PROCEEDINGS, 2014, 89 (01) :25-33

[5] Genetic Variation Among 82 Pharmacogenes: The PGRNseq Data From the eMERGE Network [J].

Bush, W. S. ;

Crosslin, D. R. ;

Owusu-Obeng, A. ;

Wallace, J. ;

Almoguera, B. ;

Basford, M. A. ;

Bielinski, S. J. ;

Carrell, D. S. ;

Connolly, J. J. ;

Crawford, D. ;

Doheny, K. F. ;

Gallego, C. J. ;

Gordon, A. S. ;

Keating, B. ;

Kirby, J. ;

Kitchner, T. ;

Manzi, S. ;

Mejia, A. R. ;

Pan, V. ;

Perry, C. L. ;

Peterson, J. F. ;

Prows, C. A. ;

Ralston, J. ;

Scott, S. A. ;

Scrol, A. ;

Smith, M. ;

Stallings, S. C. ;

Veldhuizen, T. ;

Wolf, W. ;

Volpi, S. ;

Wiley, K. ;

Li, R. ;

Manolio, T. ;

Bottinger, E. ;

Brilliant, M. H. ;

Carey, D. ;

Chisholm, R. L. ;

Chute, C. G. ;

Haines, J. L. ;

Hakonarson, H. ;

Harley, J. B. ;

Holm, I. A. ;

Kullo, I. J. ;

Jarvik, G. P. ;

Larson, E. B. ;

McCarty, C. A. ;

Williams, M. S. ;

Denny, J. C. ;

Rasmussen-Torvik, L. J. ;

Roden, D. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 100 (02) :160-169

[6] CYP4F2 genetic variant alters required warfarin dose [J].

Caldwell, Michael D. ;

Awad, Tarif ;

Johnson, Julie A. ;

Gage, Brian F. ;

Falkowski, Mat ;

Gardina, Paul ;

Hubbard, Jason ;

Turpaz, Yaron ;

Langaee, Taimour Y. ;

Eby, Charles ;

King, Cristi R. ;

Brower, Amy ;

Schmelzer, John R. ;

Glurich, Ingrid ;

Vidaillet, Humberto J. ;

Yale, Steven H. ;

Zhang, Kai Qi ;

Berg, Richard L. ;

Burmester, James K. .

BLOOD, 2008, 111 (08) :4106-4112

[7] Pharmacogenomically actionable medications in a safety net health care system [J].

Carpenter, Janet S. ;

Rosenman, Marc B. ;

Knisely, Mitchell R. ;

Decker, Brian S. ;

Levy, Kenneth D. ;

Flockhart, David A. .

SAGE OPEN MEDICINE, 2016, 4

[8] Evidence and resources to implement pharmacogenetic knowledge for precision medicine [J].

Caudle, Kelly E. ;

Gammal, Roseann S. ;

Whirl-Carrillo, Michelle ;

Hoffman, James M. ;

Belling, Mary V. ;

Klein, Teri E. .

AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2016, 73 (23) :1977-1985

[9] The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting [J].

Cavallari, L. H. ;

Beitelshees, A. L. ;

Blake, K. V. ;

Dressler, L. G. ;

Duarte, J. D. ;

Elsey, A. ;

Eichmeyer, J. N. ;

Empey, P. E. ;

Franciosi, J. P. ;

Hicks, J. K. ;

Holmes, A. M. ;

Jeng, L. J. B. ;

Lee, C. R. ;

Lima, J. J. ;

Limdi, N. A. ;

Modlin, J. ;

Obeng, A. O. ;

Petry, N. ;

Pratt, V. M. ;

Skaar, T. C. ;

Tuteja, S. ;

Voora, D. ;

Wagner, M. ;

Weitzel, K. W. ;

Wilke, R. A. ;

Peterson, J. F. ;

Johnson, J. A. .

CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2017, 10 (03) :143-146

[10]

Cavallari L.H., 2017, JACC CARDIOVASC INTE

← 1 2 3 4 5 6 7 8 9 →